Background
Long-term ART cannot change the reservoir landscape. We analyzed the reservoir composition and competency in two PWH on ART over 4 years of treatment with dasatinib.
Methods
Blood samples were collected periodically since 2019 from two PWH on ART and dasatinib to treat chronic myeloid leukemia (CML). Proviral composition was analyzed by ddPCR and IPDA in PBMCs. Proviral reactivation was assessed in CD4+ T cells by mini QVOA.
Results
First participant: 1) 50 year-old male on ART for 17 years and imatinib for 9 years that changed to dasatinib. He discontinued dasatinib after 3 years 4 months but was reintroduced after 4.3 months. 2) Median HIV-1 DNA copies per 106 PBMCs was 1724.0 on imatinib; it decreased to 219.3 after 3.5 months on dasatinib and 2.24 (IQR 0.45-25.12) from 9.5 months of treatment onwards. During discontinuation, proviral DNA was 0.63 (IQR 0.5-3.16). 3) Median intact proviruses was 158.0 after 3.5 months on dasatinib and undetectable from 9.5 months onwards. Median 3´-defective proviruses was 31.01 (IQR 13.53-48.49) after 9.5 months on dasatinib, and 8.52 (IQR 1.48-48.49) from 1 year 4 months onwards. Median 5´-defective proviruses was 8.41 (IQR 3.67-13.15) after 9.5 months on dasatinib and decreased to 6.76 copies (IQR 0.49-29.19) from this moment onwards. 4) Proviral reactivation was 2.49% (IQR 0.82-4.46) p24-gag in CD4+ T cells.
Second participant: 1) 62 year-old male on ART for 25 years and dasatinib for 4 years. 2) HIV-1 DNA copies per 106 PBMCs was 20.95 after 5 months on dasatinib and 7.59 (IQR 2.0-10.0) from 1 year 4 months onwards. 3) Median intact proviruses was 43.33 on ART and undetectable from 1year 4months on dasatinib onwards. Median 3´-defective proviruses was 128.3 (IQR 18.0-310.0) when only on ART, and 31.42 (IQR 4.88-164.17) on dasatinib for 4years and 4months. Median 5´-defective provirus was 124.35 (IQR 50.0-232.3) on ART and 8.22 (IQR 3.88-29.19) on dasatinib for 4 years and 4 months. 4) Proviral reactivation was 4.29% (IQR 0.85-7.69) p24-gag in CD4+ T cells.
Conclusions
Dasatinib treatment changed the reservoir landscape towards a more favourable scenario in which there was a reduction in intact and defective proviruses. Detectable p24-gag during proviral reactivation may proceed from defective proviruses.
Table or Figure
![]()